RT Journal Article
SR Electronic
T1 The Pivotal Role of Immune Functional Assays in Deciphering Immune Function Alterations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.19.24317497
DO 10.1101/2024.11.19.24317497
A1 Debombourg, Marion
A1 Oriol, Guy
A1 Dupre, Caroline
A1 Albert-Vega, Chloé
A1 Venet, Fabienne
A1 Rimmelé, Thomas
A1 REALISM study group
A1 Conrad, Anne
A1 Ader, Florence
A1 Alcazer, Vincent
A1 VaccHemInf study group
A1 Brengel-Pesce, Karen
A1 Fleurie, Aurore
A1 Trouillet-Assant, Sophie
A1 Mouton, William
YR 2024
UL http://medrxiv.org/content/early/2024/11/19/2024.11.19.24317497.abstract
AB Recently, immune function assessment has gained prominence in clinical settings. Immune functional assays (IFAs), involving in vitro stimulation, offer a relevant approach to complement traditional immunomonitoring methods which, while widely used, do not fully capture functional immune capabilities. Despite growing interest in IFAs, their added value remains unclear.To address this gap, our study aimed to determine if insights from IFAs could be replicated with unstimulated immunoprofiling. Using the same analytical pipeline, we compared transcriptomic profiles (Nanostring®) between stimulated (TruCulture®) and unstimulated (PaxGene™) samples from i) patients with an overstimulated immune system 3-4 days post-sepsis onset, and ii) patients undergoing immune reconstitution 6-months post-allogeneic hematopoietic stem cell transplantation (allo-HSCT).In sepsis, post-stimulation transcriptomic profiles revealed immune clusters linked to disease severity and outcomes, surpassing traditional markers like mHLA-DR, while baseline analyses failed to generate clinically relevant stratification. Similarly, allo-HSCT patients’ post-stimulation data revealed immune heterogeneity and treatment-related alterations not detected using baseline transcriptomic or cellular profiles alone.Our findings emphasize the value of IFAs in uncovering functional immune alterations that unstimulated assessments may miss, which could offer deeper insights into immune dysfunction. This study supports IFAs as complementary tools to current clinical practices, enhancing patient management with a functional view of immune system dynamics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementREALISM study :This work was supported by the French National Research Agency through a grant awarded to BIOASTER (Grant number #ANR-10-AIRT-03) and from bioMerieux, Sanofi and GSK. VaccHemInf FIGHT study : This work was supported by an internal grant from the Hospices Civils de Lyon (Appel d'Offre Jeune Chercheur 2018, to A.C.); the Region Auvergne Rhone Alpes (Pack Ambition Recherche 2019, to F.A.) This work was supported by the public grant overseen by the French National Research Agency (Chaires industrielles 2023) and supported by the Association Nationale de la Recherche et de la Technologie (ANRT) with a CIFRE fellowship granted to Marion Debombourg. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The REALISM study protocol was approved by the regional ethics committee (Comite de Protection des Personnes Sud-Est II, number 2015 42 2). The VaccHemInf protocol was approved by the regional ethics committee (Comite de Protection des Personnes Sud-Est V, Grenoble, France, number 69HCL17 0769).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yesall data in the present study are available upon reasonable request to the authors